On February 1, 2018 Scottish biotechnology company OncoBioPharm has reported that from this date it will operate as aTen Therapeutics Ltd (Press release, OncoBioPharm, FEB 1, 2018, View Source [SID1234526010]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

aTen (pronounced ‘atten’) refers to the angiotensin pathway, which plays a key role in several major diseases, and is the target of the company’s lead antibody candidate, Tensinomab.

The new name reflects the company’s commitment to exploring the full potential of its innovative technology platform, not only within oncology but across other major disease areas.

Whilst the company’s main development programme continues to explore Tensinomab’s potential to treat primary cancers and protect against developing metastases, in parallel the development team is researching angiotensin pathway modulation in the context of other serious conditions.

Managing Director, Dr Tina Flatau, said: "Although the vast therapeutic potential of Tensinomab was first demonstrated in cancer models, there is mounting evidence to suggest that angiotensin pathway-modulation could also have major benefits in the treatment of other diseases, beyond oncology. The new aTen Therapeutics brand reflects our commitment to exploring the potential of our technology fully, not just for the treatment of cancer but also within the context of other serious and life-limiting diseases."

aTen Therapeutics Ltd (registered in Scotland no 547221) is a wholly-owned subsidiary of OncoBioPharm Limited (registered in Scotland 29/7/05 no. SC288225).